Correspondence 0001193125-24-164441 from Coya Therapeutics, Inc. (COYA)
Coya Therapeutics, Inc.
Date: June 20, 2024 · CIK: 0001835022 · Accession: 0001193125-24-164441
AI Filing Summary & Sentiment
Reasoning
Letter
Re: Coya Therapeutics, Inc. (the “Company”)
June 20, 2024
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Registration Statement on Form S-3 (File No. 333- 280235)
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended, the Company hereby requests that the above-referenced Registration Statement (the “Registration Statement”) be declared effective by the Securities and Exchange Commission at 5:00 p.m., Eastern Time, on June 21, 2024, or as soon as practicable thereafter.
Please call Steven M. Skolnick of Lowenstein Sandler LLP at (973) 597-2476 to confirm the effectiveness of the Registration Statement or with any questions.
Very truly yours,
COYA THERAPEUTICS, INC.
Show Raw Text
CORRESP 1 filename1.htm CORRESP June 20, 2024 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Coya Therapeutics, Inc. (the “Company”) Registration Statement on Form S-3 (File No. 333- 280235) Ladies and Gentlemen: In accordance with Rule 461 under the Securities Act of 1933, as amended, the Company hereby requests that the above-referenced Registration Statement (the “Registration Statement”) be declared effective by the Securities and Exchange Commission at 5:00 p.m., Eastern Time, on June 21, 2024, or as soon as practicable thereafter. Please call Steven M. Skolnick of Lowenstein Sandler LLP at (973) 597-2476 to confirm the effectiveness of the Registration Statement or with any questions. Very truly yours, COYA THERAPEUTICS, INC. By: /s/ Howard Berman Name: Howard Berman Title: Chief Executive Officer (Principal Executive Officer)